Out of 19 ER+ breast tumours 15 showed no overexpression of EGFR and/or ErbB2 whereas 10 out of 18 ER− breast tumours showed overexpression of EGFR and/or ErbB2 (κ=−0.343, P=0.031). This evidence concerns the gene ESR1 and breast neoplasm.